[ad_1]
(CercleFinance.com) – Roche announces that the US FDA has approved an additional authorization application for Xofluza, as a treatment to prevent influenza in people 12 years of age and older who have been in contact with people with the flu.
With this decision, which is based on the Phase III Blockstone study whose results were recently published in the New England Journal of Medicine, Xofluza becomes the first single-dose flu drug approved for post-exposure prophylaxis.
.
[ad_2]
Source link
